Seller record · Telehealth service

Tuyo Health

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The program pages refer only to licensed compounding pharmacies, and the terms to partner pharmacies. 1 more criterion also fails; see the table below.

At a glance

Tuyo HealthTelehealth service

6/8criteria passed

Price: Semaglutide $155 a month against a listed $179; tirzepatide $235 against a listed $329
Sells: compounded semaglutide, compounded tirzepatide, Wegovy, and 11 more
FDA letters: 1 on file

Visit Tuyo Health See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A Miami-based bilingual telehealth practice led by Latino physicians, selling compounded semaglutide and tirzepatide with lab work included, brand-name Wegovy and Zepbound through insurance, sermorelin, and care for sexual health, testosterone, hair loss, birth control and primary care. Care starts with an online medical questionnaire, and no pharmacy is named.

Operating entity Tuyo Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Tuyo Health's semaglutide page; Tuyo Health's terms and conditions; Tuyo Health's website
S2	Prescription gating	PASS	Tuyo Health's weight loss page; Tuyo Health's semaglutide page
S3	Pharmacy identification	FAIL	Tuyo Health's weight loss page; Tuyo Health's terms and conditions
S4	Compounding disclosure	PASS	Tuyo Health's weight loss page; Tuyo Health's semaglutide page; Tuyo Health's tirzepatide page
S5	Analytical documentation	FAIL	Tuyo Health's weight loss page; Tuyo Health's FAQ; Tuyo Health's terms and conditions
S6	Business address	PASS	Tuyo Health's terms and conditions; Tuyo Health's privacy policy
S7	Price disclosure	PASS	Tuyo Health's semaglutide page; Tuyo Health's tirzepatide page; Tuyo Health's weight loss page; Tuyo Health's Zepbound page; Tuyo Health's website
S8	Enforcement status	PASS	FDA's website; FDA warning letter 716502

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA board-certified physician reviews each case and prescribes only if treatment is right for the patient, and the terms say care is given by the affiliated Revell Health medical groups. The home page names its physicians, led by a founder and medical director.Source: Tuyo Health's semaglutide page; Tuyo Health's terms and conditions; Tuyo Health's website.

S2PASSThe weight loss page says a buyer creates an account and then shares a medical history for pre-approval, and each product page says a provider reviews a short online health form before deciding whether treatment is right; no payment step is described before those questions.Source: Tuyo Health's weight loss page; Tuyo Health's semaglutide page.

S3FAILNo filling pharmacy is named. The program pages refer only to licensed compounding pharmacies, and the terms to partner pharmacies.Source: Tuyo Health's weight loss page; Tuyo Health's terms and conditions.

S4PASSThe weight loss and product pages state that the compounded GLP-1 medications are not approved by the FDA and are not the same as, nor affiliated with, Wegovy, Ozempic or Zepbound.Source: Tuyo Health's weight loss page; Tuyo Health's semaglutide page; Tuyo Health's tirzepatide page.

S5FAILNo certificate of analysis or lot document is published on the program pages, the answers page, the terms or the privacy policy.Source: Tuyo Health's weight loss page; Tuyo Health's FAQ; Tuyo Health's terms and conditions.

S6PASSTuyo Health, Inc. at 382 NE 191st Street, PMB 353681, Miami, FL 33179, a private mailbox, printed in the contact block of the terms and in the privacy policy. The terms name Florida law.Source: Tuyo Health's terms and conditions; Tuyo Health's privacy policy.

S7PASSCompounded semaglutide at $155 a month against a struck-through $179, and compounded tirzepatide at $235 a month against a struck-through $329, with provider visits, lab work and shipping included and no membership fee. A banner presents GLP-1 plans from $155 a month as an exclusive offer. Wegovy and Zepbound are offered through insurance with a co-pay from $25 a month, and the primary care membership is $9.99 a month.Source: Tuyo Health's semaglutide page; Tuyo Health's tirzepatide page; Tuyo Health's weight loss page; Tuyo Health's Zepbound page; Tuyo Health's website.

S8PASSFDA warning letter 716502, September 2025, names Tuyo Health, Inc. doing business as Tuyo Health at 382 NE 191st St, PMB 353681, Miami, Florida, the address its own terms print, and it reviewed the seller's own website. It alleges that claims for its compounded semaglutide and tirzepatide, among them the same active ingredient as Wegovy, Ozempic, Zepbound and Mounjaro, are false or misleading. No close-out letter appears in the index. No FDA action has halted the business, and the company continues to operate.Source: FDA's website; FDA warning letter 716502.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, Wegovy, Zepbound, metformin, sermorelin, enclomiphene, testosterone therapy, sildenafil, tadalafil, finasteride, minoxidil, birth control, primary care membership.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin

Enforcement documents on file: 1 warning letter

FDA warning letter 716502, issued September 2025, to Tuyo Health, Inc. dba Tuyo HealthClaims on Tuyo Health's website that its compounded semaglutide and tirzepatide have the same active ingredient as Wegovy, Ozempic, Zepbound and Mounjaro are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Tuyo Health

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.